TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3121179

Group type: EXPERIMENTAL
Intervention: Lentinan (LNT) in combination with tegafur (FT), LNT dosage: 2 mg weekly, FT dosage: 600 mg/day
Number of subjects: 164

Group type: COMPARATOR
Intervention: Tegafur (FT) alone
Number of subjects: 164
Study: 30428881

Group type: EXPERIMENTAL
Intervention: CARE's Community Score Card© intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 28122510

Group type: EXPERIMENTAL
Intervention: Film + 16-week exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: 16-week exercise-only program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Godin Leisure-time Exercise Questionnaire
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 60
Study: 26158245

Group type: EXPERIMENTAL
Intervention: Delirium at the initiation of weaning
Number of subjects: 70
Study: 23299364

Group type: EXPERIMENTAL
Intervention: EZ-Blocker (EZB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Left-sided double-lumen tube (DLT)
Number of subjects: 100
Study: 20834043

Group type: EXPERIMENTAL
Intervention: rMV + PT
Number of subjects: 30

Group type: COMPARATOR
Intervention: PT alone
Number of subjects: 30
Study: 18325720

Group type: EXPERIMENTAL
Intervention: Computerized dietary assessments
Number of subjects: 41

Group type: COMPARATOR
Intervention: Interviewer administered dietary assessments
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Computerized assessments
Number of subjects: 41
Study: 16579700

Group type: EXPERIMENTAL
Intervention: Adjunctive local oxygen therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Systemic antibiotics (amoxicillin, clavulanic acid, and metronidazole) without oxygen therapy
Number of subjects: 30
Study: 12757074

Group type: EXPERIMENTAL
Intervention: Pubovaginal sling (group A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vaginal wall sling (group B)
Number of subjects: 26
Study: 10473768

Group type: EXPERIMENTAL
Intervention: In-phase mode along both X- and Y-axes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-phase mode along both X- and Y-axes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-phase mode in sagittal plane motions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-phase mode along both axes in sagittal plane motions
Number of subjects: 0
Study: 8764115

Group type: EXPERIMENTAL
Intervention: Triple therapy (amoxicillin 500 mg three times a day for 2 weeks; metronidazole 400 mg three times a day for 2 weeks; bismuth subsalicylate 262 mg four times a day for 2 weeks, followed by 262 mg every day for 4-12 months)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (30 mg every day for 4-12 months)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (1 g twice a day for 4-12 months)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ascorbic acid or beta-carotene supplementation
Number of subjects: 84
Study: 2071126

Group type: EXPERIMENTAL
Intervention: 500 mg clotrimazole vaginal pessary
Number of subjects: 23

Group type: COMPARATOR
Intervention: 150 mg fluconazole capsule
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: C glabrata or C krusei
Number of subjects: 23
Study: 6680215

Group type: EXPERIMENTAL
Intervention: Continuous intra-arterial infusion of 3-5 mg/day methotrexate to a total dose of 90-120 mg
Number of subjects: 142

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Combined modality treatment
Number of subjects: 142
Study: 31060534

Group type: EXPERIMENTAL
Intervention: Bulimia Nervosa (BN) patients
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 53
Study: 28067707

Group type: EXPERIMENTAL
Intervention: DPE
Number of subjects: 120

Group type: COMPARATOR
Intervention: CSE
Number of subjects: 120

Group type: COMPARATOR
Intervention: EPL
Number of subjects: 120
Study: 26031787

Group type: EXPERIMENTAL
Intervention: Multiple Intelligences Teaching Approach (MITA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 90
Study: 23283029

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily for 1 month)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 185
Study: 20589404

Group type: EXPERIMENTAL
Intervention: Dentin desensitizer
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 64

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 64
Study: 19827055

Group type: EXPERIMENTAL
Intervention: OLM+CCB combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: OLM monotherapy
Number of subjects: 0
Study: 16760779

Group type: EXPERIMENTAL
Intervention: Minimally invasive retractor
Number of subjects: 8

Group type: COMPARATOR
Intervention: Open retractor
Number of subjects: 8
Study: 15076257

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts (Adderall)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11874821

Group type: EXPERIMENTAL
Intervention: ATRA (50 mg/m(2)/d) for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 20
Study: 10213101

Group type: EXPERIMENTAL
Intervention: 2 weeks external splinting
Number of subjects: 29

Group type: COMPARATOR
Intervention: 4 weeks external splinting
Number of subjects: 29
Study: 8666469

Group type: EXPERIMENTAL
Intervention: Life Review Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2281806

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1010
Study: 524943

Group type: EXPERIMENTAL
Intervention: Dopamine 1 mcg.kg‐1 body weight.minute‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dopamine 5 mcg.kg‐1 body weight.minute‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 10
Study: 6842336

Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg) intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 30382872

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture + Clomiphene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 27235521

Group type: EXPERIMENTAL
Intervention: MRI-based patient-specific matched guides (PSG)
Number of subjects: 137

Group type: COMPARATOR
Intervention: CT-based patient-specific matched guides (PSG)
Number of subjects: 137
Study: 24838278

Group type: EXPERIMENTAL
Intervention: Word stimuli (auditory streaming BCI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Beeps stimuli (auditory streaming BCI)
Number of subjects: 16
Study: 22832417

Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (1 mg/day for 1 month, then 2 mg/day for 2 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 20184589

Group type: EXPERIMENTAL
Intervention: Nateglinide and Valsartan (alone and in combination)
Number of subjects: 9306
Study: 18689856

Group type: EXPERIMENTAL
Intervention: Referral to a quitline service
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-practice GP management
Number of subjects: 0
Study: 15958834

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 2771
Study: 12460134

Group type: EXPERIMENTAL
Intervention: Initiated treatment (n = 450)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Declined enrollment (n = 363)
Number of subjects: 813
Study: 10357543

Group type: EXPERIMENTAL
Intervention: Volar carpal canal route of tendon transfer
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Lateral band insertion
Number of subjects: 4
Study: 7728486

Group type: EXPERIMENTAL
Intervention: Polidocanol (0.5% or 1% for telangiectasias or spider veins; 3% for varicose veins)
Number of subjects: 16804

Group type: EXPERIMENTAL
Intervention: Polidocanol
Number of subjects: 16804
Study: 1852136

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7255509

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally, 3 times daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 20
Study: 31577177

Group type: EXPERIMENTAL
Intervention: Taste-focused labels
Number of subjects: 137842
Study: 29070566

Group type: EXPERIMENTAL
Intervention: High-glycemic-load diet (HGLDiet) adherence
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Sugar intake
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Carbohydrate intake
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Glycemic load
Number of subjects: 128
Study: 25425220

Group type: EXPERIMENTAL
Intervention: Baseline plasma FGF21 levels
Number of subjects: 9697

Group type: EXPERIMENTAL
Intervention: Baseline plasma FGF21 levels (highest tertile)
Number of subjects: 9697

Group type: EXPERIMENTAL
Intervention: FGF21 levels added to CVD risk factor model
Number of subjects: 9697
Study: 24393479

Group type: EXPERIMENTAL
Intervention: artemether + lumefantrine (AL)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: artesunate + sulphamethoxypyrazine-pyrimethamine (AS-SMP)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: artesunate + amodiaquine (AS-AQ)
Number of subjects: 251
Study: 22181668

Group type: EXPERIMENTAL
Intervention: PVP‐iodine gel (10%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PVP‐iodine solution (10%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Negative control (no iodine application)
Number of subjects: 12
Study: 18793300

Group type: EXPERIMENTAL
Intervention: Dapoxetine
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1238
Study: 17608679

Group type: EXPERIMENTAL
Intervention: Pre-embedding immunolabelling procedure using monoclonal primary antibodies anti-I-CF, anti-III-CF and anti-CS.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-embedding immunolabelling procedure using monoclonal primary antibodies anti-I-CF, anti-III-CF and anti-CS.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Field emission in lens-SEM analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transmission electron microscopy (TEM) analysis
Number of subjects: 0
Study: 15029469

Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Quetiapine 100 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11486846

Group type: EXPERIMENTAL
Intervention: Carmeda‐coated Maxima‐Plus PRF oxygenator
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trillium‐coated Affinity oxygenator
Number of subjects: 60
Study: 9462572

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 331

Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 331
Study: 8168806

Group type: EXPERIMENTAL
Intervention: Aspartame 15 mg/kg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aspartame 45 mg/kg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3285215

Group type: EXPERIMENTAL
Intervention: Long-term cyclosporine
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Short-term cyclosporine followed by azathioprine and prednisolone
Number of subjects: 417

Group type: COMPARATOR
Intervention: Azathioprine and prednisolone only
Number of subjects: 417
Study: 31844963

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided steroid wrist injections
Number of subjects: 45

Group type: COMPARATOR
Intervention: Consensus statements on clinical indications
Number of subjects: 45
Study: 31370873

Group type: EXPERIMENTAL
Intervention: HD-tDCS treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 100
Study: 29192534

Group type: EXPERIMENTAL
Intervention: Intensive Language-Action Therapy (ILAT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intensive Naming Therapy (INT)
Number of subjects: 18
Study: 25907157

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy with support to taper or discontinue antidepressant treatment (MBCT-TS)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Maintenance antidepressants
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Both treatments (MBCT-TS and maintenance antidepressants)
Number of subjects: 424
Study: 23297921

Group type: EXPERIMENTAL
Intervention: Auditory training in interrupted noise (7 sessions of 1 hour each)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Auditory training in continuous noise (7 sessions of 1 hour each)
Number of subjects: 24
Study: 22151936

Group type: COMPARATOR
Intervention: 4% hydroquinone cream
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 20% azelaic acid cream
Number of subjects: 29
Study: 19401349

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 912

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 912
Study: 16918640

Group type: EXPERIMENTAL
Intervention: 1.8 mg/day of konjac ceramide in milk sugar (ceramide group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Milk sugar (control group)
Number of subjects: 50
Study: 14751655

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily for 6 weeks, then increased to 8 mg for an additional 6 weeks
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg after up-titration
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Perindopril in elderly African-Americans (>65 years of age)
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Perindopril in diabetic African-Americans
Number of subjects: 1412
Study: 10922421

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014
Study: 9378691

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day during luteal phase
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo during luteal phase
Number of subjects: 15
Study: 7901174

Group type: EXPERIMENTAL
Intervention: 15 mg of quazepam for eight weeks
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 0.5 mg of triazolam for eight weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo for four days followed by placebo for another week
Number of subjects: 65
Study: 3982917

Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg/kg body weight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30843141

Group type: COMPARATOR
Intervention: Tiotropium 5 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol (2 μg, 5 μg, 10 μg)
Number of subjects: 0
Study: 29176462

Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy (CBT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Internet Pain Education
Number of subjects: 25
Study: 26014476

Group type: EXPERIMENTAL
Intervention: Treatment group (vegetables packaged with cartoon characters and stickers)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (generic packaged vegetables)
Number of subjects: 24
Study: 23313603

Group type: EXPERIMENTAL
Intervention: High arousal and negative valence (anxious condition)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Positive valence
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High and low valence
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Valence and arousal
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: ERN minus CRN difference
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Affect-related differences
Number of subjects: 121
Study: 22137068

Group type: EXPERIMENTAL
Intervention: Spironolactone (target dose 30 mg daily)
Number of subjects: 3515

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 3515
Study: 19005996

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polyethylene glycol (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polyethylene glycol (Group C)
Number of subjects: 100
Study: 17539316

Group type: EXPERIMENTAL
Intervention: Isatis root eyedrops, administered six times each day for 7 days.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hailun eyedrops (levofloxacin eyedrops), administered six times each day for 7 days.
Number of subjects: 200
Study: 15129409

Group type: EXPERIMENTAL
Intervention: High-power ultrasound applied to the trigger points before stretching the muscle
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional ultrasound
Number of subjects: 72
Study: 11820329

Group type: EXPERIMENTAL
Intervention: Naloxone (1.2 3 cm3)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl saline; 3 cm3)
Number of subjects: 9
Study: 7921715

Group type: EXPERIMENTAL
Intervention: Alprazolam and exposure
Number of subjects: 154
Study: 3073808

Group type: EXPERIMENTAL
Intervention: 9 months' treatment with rifampicin and isoniazid, supplemented by ethambutol for the first 8 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 18 months' treatment with rifampicin and isoniazid, supplemented by ethambutol for the first 8 weeks
Number of subjects: 73
Study: 31832789

Group type: EXPERIMENTAL
Intervention: Single intravenous bolus of cyclosporine
Number of subjects: 969
Study: 28934258

Group type: EXPERIMENTAL
Intervention: Financial incentives to improve hypertension care
Number of subjects: 65
Study: 25936465

Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham manual contact
Number of subjects: 42
Study: 23938175

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 135
Study: 21864362

Group type: EXPERIMENTAL
Intervention: Non-invasive Interactive Neurostimulation (NIN) therapy using the InterX device, 8 sessions over 3 post-op days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard hospital course of pain medication and rehabilitation
Number of subjects: 61
Study: 18556359

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography (CE-MRA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 3D time-of-flight MR angiography (TOF MRA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both CE-MRA and TOF MRA
Number of subjects: 52
Study: 16581404

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg per day for 30 days then up to 10 mg per day thereafter, n=128)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo (n=120)
Number of subjects: 248
Study: 12921641

Group type: EXPERIMENTAL
Intervention: Nasea (group A, n = 43)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Ondansetron (group B, n = 42)
Number of subjects: 85
Study: 11910610

Group type: EXPERIMENTAL
Intervention: Menopause Rating Scale (MRS)
Number of subjects: 306
Study: 9415856

Group type: EXPERIMENTAL
Intervention: Parenteral naloxone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Marlowe‐Crowne Social Desirability Scale (MCSDS)
Number of subjects: 30
Study: 7965483

Group type: COMPARATOR
Intervention: Standard ORS solution
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Diluted ORS solution
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) therapy
Number of subjects: 61
Study: 3109959

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation initiated on day 2
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ovarian stimulation initiated on day 4
Number of subjects: 104
Study: 31704268

Group type: EXPERIMENTAL
Intervention: Interocclusal splints postoperatively
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no splints)
Number of subjects: 40
Study: 29402422

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Aspirin only (ASA)
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 1525

Group type: COMPARATOR
Intervention: ASA
Number of subjects: 1525
Study: 27935521

Group type: EXPERIMENTAL
Intervention: Leucine supplementation (5 g leucine/meal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 26333227

Group type: EXPERIMENTAL
Intervention: Shugan Yiyang Capsules (Group A)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oral levocarnitine (Group B)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination of Shugan Yiyang Capsules and oral levocarnitine (Group C)
Number of subjects: 135
Study: 23127584

Group type: EXPERIMENTAL
Intervention: Bright light exposure at 19:00 or 21:00h
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bright light exposure
Number of subjects: 27
Study: 22022855

Group type: EXPERIMENTAL
Intervention: Peer-assisted multi-component behavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-matched HIV health education and counseling (Control)
Number of subjects: 0
Study: 18550333

Group type: EXPERIMENTAL
Intervention: Records request included with a colorectal cancer screening survey (with-survey group)
Number of subjects: 890

Group type: COMPARATOR
Intervention: Request in a separate mailing following a completed survey (after-survey group)
Number of subjects: 890
Study: 16482066

Group type: EXPERIMENTAL
Intervention: 30 g of NUTRIOSE FB daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 45 g of NUTRIOSE FB daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (22.5 g of pure maltodextrin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NUTRIOSE FB (both doses)
Number of subjects: 48
Study: 14606984

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins (general)
Number of subjects: 0
Study: 10759337

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 133

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 133